Technical Analysis for VKTX - Viking Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | -1.28% | |
| Gapped Up | Strength | -1.28% | |
| Oversold Stochastic | Weakness | -1.28% | |
| Slingshot Bearish | Bearish Swing Setup | -1.24% | |
| Stochastic Buy Signal | Bullish | -1.24% | |
| Lower Bollinger Band Walk | Weakness | -1.24% | |
| Multiple of Ten Bullish | Other | -1.24% | |
| Wide Bands | Range Expansion | -1.24% | |
| Oversold Stochastic | Weakness | -1.24% | |
| Doji - Bullish? | Reversal | 3.58% |
| Alert | Time |
|---|---|
| Down 1% | 5 minutes ago |
| Down 2 % | about 23 hours ago |
| Down 1% | about 24 hours ago |
| 1.5x Volume Pace | about 24 hours ago |
| Rose Above Previous Day's High | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 10/23/2024
Viking Therapeutics, Inc. Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program includes VK0612, an orally available drug candidate for the treatment of type 2 diabetes. The company is also developing VK5211, an orally available drug candidate, which has completed Phase I trial for the treatment of cancer cachexia, a disease characterized by an uncontrolled decline in muscle mass. In addition, it is developing VK0214, a novel liver-selective thyroid hormone receptor beta agonist for lipid disorders, such as dyslipidemia and nonalcoholic steatohepatitis, as well as other preclinical programs for metabolic diseases and anemia. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Disease Alcohol Diabetes Medication Treatment Of Cancer Obesity Lipid Metabolic Disease Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Anemia Thyroid Geriatrics Dyslipidemia Rehabilitation Medicine Endocrine Disorders Cachexia Endocrine Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 99.41 |
| 52 Week Low | 11.545 |
| Average Volume | 4,462,392 |
| 200-Day Moving Average | 62.15 |
| 50-Day Moving Average | 64.24 |
| 20-Day Moving Average | 64.06 |
| 10-Day Moving Average | 57.13 |
| Average True Range | 4.61 |
| RSI (14) | 35.06 |
| ADX | 22.38 |
| +DI | 18.54 |
| -DI | 31.41 |
| Chandelier Exit (Long, 3 ATRs) | 67.89 |
| Chandelier Exit (Short, 3 ATRs) | 61.49 |
| Upper Bollinger Bands | 82.40 |
| Lower Bollinger Band | 45.72 |
| Percent B (%b) | 0.16 |
| BandWidth | 57.27 |
| MACD Line | -4.06 |
| MACD Signal Line | -2.10 |
| MACD Histogram | -1.9518 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 55.49 | ||||
| Resistance 3 (R3) | 55.55 | 54.30 | 54.83 | ||
| Resistance 2 (R2) | 54.30 | 53.29 | 54.27 | 54.61 | |
| Resistance 1 (R1) | 52.91 | 52.67 | 52.29 | 52.85 | 54.39 |
| Pivot Point | 51.66 | 51.66 | 51.34 | 51.63 | 51.66 |
| Support 1 (S1) | 50.27 | 50.65 | 49.65 | 50.21 | 48.67 |
| Support 2 (S2) | 49.02 | 50.03 | 48.99 | 48.45 | |
| Support 3 (S3) | 47.63 | 49.02 | 48.23 | ||
| Support 4 (S4) | 47.57 |
